A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype

ConclusionsZos plus GO elicited appreciable ORR for an elderly patient population with RR AML. The greater OS of the P-gp  + subgroup vs. the P-gp‒ subgroup suggests that patients with P-gp + leukemic blasts were being more effectively targeted by GO with Zos co-therapy. The poorer OS of the P-gp‒ subgroup suggests activity of Zos-insensitive multidrug resistant mechanisms.Clinical trials.gov identifierNCT00233909; First posted October 06, 2005.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research